Advertisement
U.S. markets closed

Becton, Dickinson and Company (BDX)

NYSE - NYSE Delayed Price. Currency in USD
247.45+0.92 (+0.37%)
At close: 04:00PM EDT
246.50 -0.95 (-0.38%)
After hours: 06:10PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close246.53
Open246.73
Bid247.71 x 800
Ask247.80 x 900
Day's Range245.33 - 248.42
52 Week Range229.86 - 287.32
Volume994,158
Avg. Volume1,472,524
Market Cap71.489B
Beta (5Y Monthly)0.44
PE Ratio (TTM)56.50
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.80 (1.54%)
Ex-Dividend DateMar 07, 2024
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
8% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BDX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Becton, Dickinson and Company
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    11 days agoArgus Research
View more
  • Zacks

    Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

    The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

  • Zacks

    QIAGEN (QGEN) Partners With IPPA to Raise TB Screening Awareness

    QIAGEN's (QGEN) collaboration with IPPA follows the updated CDC guidelines for TB screening for immigrants in the United States.

  • Reuters

    UPDATE 3-Becton Dickinson ramps up syringe production in US amid China quality concerns

    Becton Dickinson said on Thursday it has increased production of medical syringes in the United States after the country's drug regulator recommended not using some China-made syringes as part of its ongoing quality probe. The U.S.-based medical equipment maker — one of the world's largest syringe suppliers — said it had increased manufacturing in its Nebraska and Connecticut facilities, since the U.S. Food and Drug Administration first raised concerns about China-made syringes in November. The FDA had said last year it was looking into reports of leaks, breakages and other quality problems with plastic syringes manufactured in China and that it may prevent such syringes from entering the U.S. market, if necessary.